Alzheimer's Disease Clinical Trial
Official title:
Effects and Mechanisms of Aerobic Exercises Combined With Dual-task Training in Cognitive Function in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease
Verified date | February 2014 |
Source | National Taiwan University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | Taiwan: Department of Health |
Study type | Interventional |
Recent studies have shown that aerobic exercises and dual-task training are effective in
improving overall cognitive function in patients with cognitive impairment or dementia.
However, the biological mechanisms are unknown in humans. It also remains unclear regarding
whether carrying APOEε4 genotype or not would influence the effects. Therefore, the three
main purposes of this study are: (1) to investigate the effects of a 3-month aerobic
exercises combined with dual-task training on memory and executive cognitive functions in
patients with mild cognitive impairment (MCI) and in those with early Alzheimer's disease
(AD); (2) to compare the differences in training effects between patients who carry APOEε4
genotype and those who do not carry this genotype; and (3) to investigate the biological
mechanisms of the exercise training effects on memory and executive cognitive function in
these patients. The biological mechanisms of interest will include the blood Aβ1-40 and
Aβ1-42 level, insulin, fasting glucose, cytokine, integrity of brain fiber tracts, and
cerebral blood flow.
We will conduct a randomized controlled clinical trial. A total of 70 patients with MCI or
AD will be recruited. The participants will be randomly assigned to the experimental group
or the control group. Both groups will receive three 90-minute exercise sessions per week
for 12 weeks. For the experimental group, the exercise program will include moderate
intensity aerobic exercises and dual-task training; whereas for the control group, the
training program will include gentle stretching exercises. Both groups will receive
examinations on outcome variables, including blood Aβ1-40 and Aβ1-42 level, insulin, fasting
glucose, cytokine,integrity of brain fiber tracts, cerebral blood flow, cognitive function,
and dual task performance at baseline, post-training, and after a 3-month follow-up period.
Differences on the aforementioned outcomes brought by the 12-week training programs will be
compared between the experimental and control groups. Exercise effects between patients who
carry APOEε4 genotype and those who do not will also be examined.
Results of this study will provide relevant clinical evidence for the effects of aerobic
exercises combined with dual-task training on patients with MCI and mild AD; and will
provide further understanding of the mechanisms mediating these effects.
Status | Completed |
Enrollment | 19 |
Est. completion date | December 2013 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years to 90 Years |
Eligibility |
Inclusion Criteria: - mild cognitive impairment or mild AD. Exclusion Criteria: - neurological disorders or psychiatric disorders, or any other systematic diseases that would affect their walking ability |
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes of Memory and executive function related neuropsychological test | Changes from baseline in neuropsychological test at 3 months and 6 months | No | |
Secondary | Changes of muscle strength of upper and lower extremity and walking speed | Changes from baseline in muscle strength of upper and lower extremity and walking speed at 3 months and 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT01922258 -
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
|
Phase 3 |